The information on this page comes from the UK Activity Report.
Click here for further details

Oxford Biomedica Oxford Biomedica is to shed about nine of the 90 jobs at its gene therapy business in Oxford. 01-Sep-2008 Oxford Biomedica has acquired Oxxon Therapeutics, the Oxford-based therapeutic vaccines company, for £16m. 13-Mar-2007 Oxford Biomedica is to raise £30m in a share placing to fund the commercial development of its gene therapy research business. 17-Nov-2005 Oxford Biomedica, the gene therapy company with a market capitalisation of £85m, has received a takeover approach from an unnamed company. 20-Jan-2005 Oxford Biomedica has won a £0.5m grant to research treatments for Haemophilia A, as part of a £4m investment in gene therapy by the Department of Health. 31-Mar-2004 Oxford Biomedica is planning to raise £20m in a rights issue, in order to strengthen its balance sheet and prepare for the negotiation of new drug licensing deals. 17-Sep-2003 Oxford Biomedica is planning to raise up to £30m in a share offer in order to fund international expansion and clinical trials for new gene therapy-based products. 05-Mar-2001 Oxford Biomedica is seeking a partner to fund the development of its TroVax cancer vaccine, and is also planning to seek a listing on London's main market. 03-Jan-2001 Oxford Biomedica has raised £8.5m in a share placing in order to set up a new gene division, and the proceeds will be spent on the recruitment of scientists and the marketing of two new technologies. 10-Aug-2000 Oxford Biomedica has raised a further £5m in a share issue for the development of gene therapy, and is looking to move from the Alternative Investment Market to a full stockmarket listing. 19-Jan-2000 Oxford Biomedica is forming a joint venture with ViroMed of South Korea to develop gene therapies against cancer. 20-May-1999 Oxford Biomedica is planning to raise £3.6m in a rights issue to fund clinical trials for its gene therapy projects. 04-Mar-1999 Oxford Biomedica is forming an alliance with Rhone Poulenc's RPR Gencell division in the US to develop gene therapy technology for heart disease. 14-Dec-1998 Oxford Biomedica is planning to raise £6m in a rights issue, and plans to begin clinical trials on two cancer drugs this year. 27-Feb-1998 Oxford Biomedica is to undertake joint research into gene therapy with Rhone-Poulenc Rorer of the US, and hopes to reach similar agreements with other US companies. 27-Jan-1998 Oxford Biomedica is seeking additional funds of up to £10m to fund research into cancer treatments, following its failure to raise sufficient funds when it launched on the Alternative Investment Market in December. 04-Aug-1997 Oxford Biomedica, the gene-therapy concern, is planning a public share offer in November in order to raise £5m for the funding of a lease on a site in Oxford and the recruitment of up to 30 staff. 09-Sep-1996 The information on this page comes from the UK Activity Report. Click here for further details Copyright UK Business Park 1995-2009